Under the $534,000.00 Project Grant awarded by the Defense Health Agency through the Military Medical Research and Development program (CFDA 12.420), the Dana-Farber Cancer Institute, Inc. (doing business as DFCI) will conduct research to define the role of the androgen receptor in BRCA1/2-deficient prostate cancer. This translational research aims to improve understanding of disease dependencies and develop new treatment approaches for this challenging cancer type. DFCI, a non-profit hospital and cancer research center in Boston, Massachusetts, has a history of collaborating with federal agencies like the NIH, DoD, and VA on cancer-related research and services.
Generated 5/7/24, 10:39 AM